Director/PDMR Shareholding

26 June 2015

Synergy Health plc ("Synergy", the "Company", or the "Group")

Director/PDMR Shareholding

The Company announces the following transactions by a person discharging managerial responsibilities ("PDMR"), in Synergy Health plc ordinary shares of 0.625 pence each ("Ordinary Shares") and the consequent allocations of Ordinary Shares to the LTIP Co-Invest scheme:

1) Mr Gavin Hill, Group Finance Director, purchased 3,400 Ordinary shares at a price of 1,751 pence on 23 June 2015 and allocated these shares to the LTIP Co-Invest scheme. Mr Hill also exercised options over 5,500 Ordinary Shares under the Company's LTIP scheme. These Ordinary Shares have been retained by Mr Hill and have been allocated to the Company's LTIP Co-Invest Scheme. As a result of these allocations to the Company's LTIP Co-Invest Scheme, Mr Hill has been granted an LTIP Co-Invest option of 17,800 options. Following the transactions Mr Hill has an interest in 48,784 Ordinary Shares, representing 0.08% of the Company's issued share capital.

2) Dr Adrian Coward, Chief Operating Officer, exercised options over 1,298 Ordinary Shares under the Company's Save As You Earn Scheme and retained the Ordinary Shares. Dr Coward also exercised options over 10,118 Ordinary Shares under the Company's LTIP scheme and the Ordinary Shares retained. These Ordinary Shares have been allocated to the LTIP Co-Invest Scheme. As a result of the allocation to the Company's LTIP Co-Invest Scheme, Dr Coward has been granted an LTIP Co-Invest option of 22,832 options. Following the transactions Dr Coward has an interest in 49,419 Ordinary Shares, representing 0.08% of the Company's issued share capital.

3) Mr Jonathan Turner, Group Company Secretary, exercised options over 1,298 Ordinary Shares under the Company's Save As You Earn Scheme. These Ordinary Shares have been retained by Mr Turner and shares have been allocated to the Company's LTIP Co-Invest Scheme. As a result of the allocation to the Company's LTIP Co-Invest Scheme, Mr Turner has been granted an LTIP Co-Invest option of 2,596 options. Following the transaction Mr Turner has an interest in 1,298 Ordinary Shares, representing 0.00% of the Company's issued share capital.

4) Mr Andrew Mclean, CEO AST and Laboratories, purchased 5,684 Ordinary Shares at a price range of between 1,753 pence and 1,759.82 pence on 24 June 2015 and allocated these shares to the LTIP Co-Invest scheme. As a result of the above allocation to the Company's LTIP Co-Invest Scheme, Mr Mclean has been granted an additional LTIP Co-Invest option of 11,368 options. Following the transaction Mr Mclean has an interest in 13,340 Ordinary Shares, representing 0.02% of the Company's issued share capital.

5) Dr Richard Steeves, Chief Executive Officer, purchased 22,722 Ordinary Shares at a range of prices between 1,743.68 pence and 1,755 pence on 24 June 2015. Dr Steeves also exercised options over 2,950 Ordinary shares under the Company's Save As You Earn scheme. These Ordinary shares will be retained by Dr Steeves and allocated to the LTIP Co-Invest Scheme. As a result of the allocation to the Company's LTIP Co-Invest Scheme, Dr Steeves had been granted an LTIP Co-Invest option of 46,734 options. Following the transactions Dr Steeves has an interest in 1,932,703 Ordinary Shares, representing 3.27% of the Company's issued share capital

The LTIP Co-Invest arrangement requires that the participant to whom the award is to be made invests in Ordinary Shares in the Company and continues to hold those Ordinary Shares throughout the three year measurement period. At the end of the measurement period, depending upon the growth in earnings per share of the Company over the measurement period, the participant will receive a number of "matching" shares at nominal value under the LTIP Co-Invest.

For further information:

Jonathan Turner, Group Company Secretary +44 (0) 1793 891 893